Neurotrophic ACTH4-9analogue therapy normalizes electroencephalographic alterations in chronic experimental allergic encephalomyelitis

Alterations in plasma lipoproteins and apolipoproteins in experimental allergic encephalomyelitis.

Plasma lipoproteins were investigated during the active clinical phase of experimental allergic encephalomyelitis (EAE), a demyelinating disease of the central nervous system. Three groups of Lewis rats were compared: untreated controls, Freund's adjuvant-treated controls (FAC), and rats receiving one injection of myelin in Freund's adjuvant. After onset of clinical symptoms, 12 and 16 days aft...

Metabolomics approaches in experimental allergic encephalomyelitis.

A myelin basic protein (MBP)-induced experimental allergic encephalomyelitis (EAE) involves paraplegia due to a reversible thoracolumbar spinal cord impairment. The aims of this study were thus to find significant metabolic biomarkers of inflammation and identify the site of inflammation in the central nervous system (CNS) during the acute signs in of the disease using metabolomics. All the EAE...

Experimental Allergic Encephalomyelitis in Oxygen Immunosuppression : Modification

Myelin-binding antibodies in experimental "allergic" encephalomyelitis.

Antibodies with a specificity for myelin, as demonstrated by immunofluorescence, are present in the sera of rabbits injected with spinal cord. These antibodies react with both adult rabbit and human spinal cord but not with unmyelinated areas of neonatal human spinal cord.

Alpha-fetoprotein suppresses experimental allergic encephalomyelitis.

Experimental allergic encephalomyelitis (EAE), induced in guinea pigs by immunization with myelin basic protein (MBP) or whole CNS homogenate was successfully treated, as well as partially prevented, by daily administration of fetal alpha-fetoprotein (alpha FP). alpha FP which is produced in high quantities during pregnancy can inhibit both the cell-mediated immune response to MBP and the bindi...